Direct anti-cancer effect of oncostatin M on chondrosarcoma

International Journal of Cancer

Volumn 128, Issue 8, 2011, Pages 1822-1835

  David, Emmanuelle ^a,b   Guihard, Pierre ^a,b   Brounais, Bénédicte ^a,b   Riet, Anne ^a,b   Charrier, Céline ^a,b   Battaglia, Séverine ^a,b   Gouin, Franãois ^a,b,c   Ponsolle, Stéphanie ^c   Bot, Ronan Le ^d   Richards, Carl D ^e   Heymann, Dominique ^a   Rédini, Franãoise ^a,b   Blanchard, Frédéric ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Atlantic Bone Screen   (France)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

adenovirus; angiogenesis; chondrosarcoma; oncostatin M; osteolysis

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN TYPE 10; COLLAGENASE 3; JANUS KINASE 3; ONCOSTATIN M; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN P53; STAT1 PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE ATROPHY; BONE REMODELING; CANCER CELL CULTURE; CANCER INHIBITION; CARTILAGE CELL; CARTILAGE MATRIX; CELL CYCLE ARREST; CELL DIFFERENTIATION; CHONDROSARCOMA; CONTROLLED STUDY; FLU LIKE SYNDROME; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPERTROPHY; MALE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 79951994543     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25776     Document Type: Article

References (49)

1. Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC,. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005; 6: 599-607. (Pubitemid 41051938)
2. Aigner T,. Towards a new understanding and classification of chondrogenic neoplasias of the skeletonâbiochemistry and cell biology of chondrosarcoma and its variants. Virchows Arch 2002; 441: 219-30.
3. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, Bovee JV,. The clinical approach towards chondrosarcoma. Oncologist 2008; 13: 320-9. (Pubitemid 351679908)
4. Bovee JV, Hogendoorn PC, Wunder JS, Alman BA,. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010; 10: 481-8.
5. Schrage YM, Machado I, Meijer D, Briaire-de Bruijn I, van den Akker BE, Taminiau AH, Kalinski T, Llombart-Bosch A, Bovee JV,. COX-2 expression in chondrosarcoma: a role for celecoxib treatment? Eur J Cancer 2010; 46: 616-24.
6. Schrage YM, Lam S, Jochemsen AG, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC, Bovee JV,. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro. J Cell Mol Med 2009; 13: 2843-52.
7. Mori K, Redini F, Gouin F, Cherrier B, Heymann D,. Osteosarcoma: current status of immunotherapy and future trends (review). Oncol Rep 2006; 15: 693-700.
8. Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Redini F,. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res 2010; 16: 2363-74.
9. Boeuf S, Kunz P, Hennig T, Lehner B, Hogendoorn P, Bovee J, Richter W,. A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. J Pathol 2008; 216: 158-66.
10. Mackie EJ, Ahmed YA, Tatarczuch L, Chen KS, Mirams M,. Endochondral ossification: how cartilage is converted into bone in the developing skeleton. Int J Biochem Cell Biol 2008; 40: 46-62. (Pubitemid 350052658)
11. Hattori T, Muller C, Gebhard S, Bauer E, Pausch F, Schlund B, Bosl MR, Hess A, Surmann-Schmitt C, von der Mark H, de Crombrugghe B, von der Mark K,. SOX9 is a major negative regulator of cartilage vascularization, bone marrow formation and endochondral ossification. Development 2010; 137: 901-11.
12. Behonick DJ, Xing Z, Lieu S, Buckley JM, Lotz JC, Marcucio RS, Werb Z, Miclau T, Colnot C,. Role of matrix metalloproteinase 13 in both endochondral and intramembranous ossification during skeletal regeneration. PLoS One 2007; 2: e1150.
13. Usui M, Xing L, Drissi H, Zuscik M, O'Keefe R, Chen D, Boyce BF,. Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J Bone Miner Res 2008; 23: 314-25. (Pubitemid 351304662)
14. Kishimoto K, Kitazawa R, Kurosaka M, Maeda S, Kitazawa S,. Expression profile of genes related to osteoclastogenesis in mouse growth plate and articular cartilage. Histochem Cell Biol 2006; 125: 593-602. (Pubitemid 43673522)
15. Blanchard F, Duplomb L, Baud'huin M, Brounais B,. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev 2009; 20: 19-28.
16. Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, Khammari A, Dreno B, Jacques Y, Blanchard F, Godard A,. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes. J Pathol 2008; 216: 451-9.
17. Chipoy C, Berreur M, Couillaud S, Pradal G, Vallette F, Colombeix C, Redini F, Heymann D, Blanchard F,. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res 2004; 19: 1850-61. (Pubitemid 41103437)
18. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B, Veale DJ,. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 2006; 54: 3152-62. (Pubitemid 44622086)
19. Heymann D, Godard A, Raher S, Ringeard S, Lassort D, Blanchard F, Harb J,. Human interleukin for DA cells/leukemia inhibitory factor and oncostatin M enhance membrane expression of intercellular adhesion molecule-1 on melanoma cells but not the shedding of its soluble form. Cytokine 1995; 7: 111-7.
20. Hui W, Cawston TE, Richards CD, Rowan AD,. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL. Arthritis Res Ther 2005; 7: R57-64.
21. Taupin JL, Miossec V, Pitard V, Blanchard F, Daburon S, Raher S, Jacques Y, Godard A, Moreau JF,. Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine binding domains. J Biol Chem 1999; 274: 14482-9.
22. El Mabrouk M, Sylvester J, Zafarullah M,. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes. Biochim Biophys Acta 2007; 1773: 309-20.
23. de Hooge AS, van de Loo FA, Bennink MB, Arntz OJ, Fiselier TJ, Franssen MJ, Joosten LA, Van Lent PL, Richards CD, van den Berg WB,. Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M: a comparative study in gene-deficient mice. Arthritis Rheum 2003; 48: 1750-61. (Pubitemid 36682384)
24. Palmqvist P, Persson E, Conaway HH, Lerner UH,. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 2002; 169: 3353-62. (Pubitemid 35013185)
25. Bishop KA, Meyer MB, Pike JW,. A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression. Mol Endocrinol 2009; 23: 2095-110.
26. Repovic P, Fears CY, Gladson CL, Benveniste EN,. Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene 2003; 22: 8117-24. (Pubitemid 37487302)
27. Barksby HE, Hui W, Wappler I, Peters HH, Milner JM, Richards CD, Cawston TE, Rowan AD,. Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes: implications for cartilage destruction and repair. Arthritis Rheum 2006; 54: 540-50. (Pubitemid 43228630)
28. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J,. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003; 84: 151-9. (Pubitemid 37363158)
29. Brounais B, Chipoy C, Mori K, Charrier C, Battaglia S, Pilet P, Richards CD, Heymann D, Redini F, Blanchard F,. Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo. Clin Cancer Res 2008; 14: 5400-9.
30. Bellido T, O'Brien CA, Roberson PK, Manolagas SC,. Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 1998; 273: 21137-44. (Pubitemid 28385402)
31. Chipoy C, Brounais B, Trichet V, Battaglia S, Berreur M, Oliver L, Juin P, Redini F, Heymann D, Blanchard F,. Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene 2007; 26: 6653-64. (Pubitemid 47573687)
32. Brounais B, David E, Chipoy C, Trichet V, Ferre V, Charrier C, Duplomb L, Berreur M, Redini F, Heymann D, Blanchard F,. Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone 2009; 44: 830-9.
33. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PC,. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009; 219: 294-305.
34. Gouin F, Ory B, Redini F, Heymann D,. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 2006; 119: 980-4. (Pubitemid 44116903)
35. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F,. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
36. Kerr C, Langdon C, Graham F, Gauldie J, Hara T, Richards CD,. Adenovirus vector expressing mouse oncostatin M induces acute-phase proteins and TIMP-1 expression in vivo in mice. J Interferon Cytokine Res 1999; 19: 1195-205. (Pubitemid 29502787)
37. Kunisada T, Miyazaki M, Mihara K, Gao C, Kawai A, Inoue H, Namba M,. A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation. Int J Cancer 1998; 77: 854-9. (Pubitemid 28378133)
38. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, et al,. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010; 49: 40-51.
39. Guerne PA, Lotz M,. Interleukin-6 and transforming growth factor-beta synergistically stimulate chondrosarcoma cell proliferation. J Cell Physiol 1991; 149: 117-24. (Pubitemid 21910172)
40. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F, Behrmann I,. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 1999; 18: 3742-53. (Pubitemid 29338507)
41. Lacreusette A, Barbieux I, Nguyen JM, Pandolfino MC, Dreno B, Jacques Y, Godard A, Blanchard F,. Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells. J Pathol 2009; 217: 665-76.
42. Klausen P, Pedersen L, Jurlander J, Baumann H,. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene 2000; 19: 3675-83. (Pubitemid 30608489)
43. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S,. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001; 33: 346-56. (Pubitemid 32119024)
44. Levy DE, Gilliland DG,. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 2000; 19: 2505-10. (Pubitemid 30339206)
45. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C,. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 1999; 13: 1361-6. (Pubitemid 29270242)
46. Legeai-Mallet L, Benoist-Lasselin C, Munnich A, Bonaventure J,. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone 2004; 34: 26-36. (Pubitemid 38142431)
47. Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS,. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene 1999; 18: 1023-32. (Pubitemid 29086279)
48. Ouyang P,. An in vitro model to study mesenchymal-epithelial transformation. Biochem Biophys Res Commun 1998; 246: 771-6. (Pubitemid 28420933)
49. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ,. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 2004; 113: 379-89. (Pubitemid 38544182)